The significance of multiple TP53 mutations as a marker of poor prognosis in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has been widely recognized and integrated into international consensus guidelines. Here, TP53 is linked to acute myeloid leukemia.